Skip to content
AnalystLens

DEXCOM INC 8-K Report, Financial Results (Oct 30, 2025)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed October 30, 2025
Period End
October 30, 2025
Security
DXCM
In the record · 2016–202610-K1110-Q328-K134

DXCM filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 134 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · May ’17May ’17
  2. Material agreement8-K · May ’20May ’20
  3. Leadership change8-K · Aug ’22Aug ’22
  4. Leadership change8-K · Sep ’26Sep ’26

01—Abstract

Summary

Summary of the 8-K filed October 30, 2025. Cited figures are marked; the original filing is the authoritative source.

DexCom (DXCM) reported third-quarter 2025 results on October 30, 2025, with revenue up 22% year-over-year to $1.209 billiona (20% organic, excluding $11.4 million of FX impact).

Growth was broad-based: U.S. revenue rose 21% and international revenue rose 22% on a reported basis. GAAP operating income reached $242.5 millionb (20.1% margin), up 480 basis points, while non-GAAP operating income was $272.9 million (22.6% margin), up 130 basis points. GAAP diluted EPS was $0.70 and non-GAAP diluted EPS was $0.61.

Note that GAAP net income was boosted by $82.7 millionc of income from equity investments, which management excludes from non-GAAP results. Management raised full-year 2025 revenue guidance to $4.630-$4.650 billion (approximately 15% growth) and updated margin guidance: non-GAAP gross margin of about 61%, non-GAAP operating margin of about 20-21%, and Adjusted EBITDA margin of about 29-30%. Jake Leach is serving as president and interim CEO, and the company highlighted a $3.32 billion cash and marketable securities balance with an undrawn revolver, which supports continued production capacity expansion.

Quality of earnings considerations: hardware revenue fell 19% year-over-year to $34.2 milliond, while sensor and other revenue grew 23%, reinforcing recurring-revenue mix. Operating expenses included $22.7 million of business transition costs tied to workforce reductions and San Diego office rent.

The company is also pursuing its patent litigation against Abbott, with related legal costs excluded from non-GAAP metrics. Overall, the quarter shows strong top-line momentum and margin expansion, with the key watch items being sustainability of growth, hardware decline, and the leadership transition.

02—Key points

Key Highlights

  1. Revenue grew 22% YoY to $1.209 billion (20% organic); U.S. up 21%, international up 22%
  2. GAAP operating margin expanded 480 bps to 20.1%; non-GAAP operating margin rose 130 bps to 22.6%
  3. GAAP diluted EPS of $0.70 vs. $0.34 a year ago; non-GAAP diluted EPS of $0.61 vs. $0.45, with GAAP boosted by $82.7M of equity-investment income
  4. FY2025 revenue guidance raised to $4.630-$4.650 billion (~15% growth); non-GAAP gross margin ~61%, operating margin ~20-21%, Adjusted EBITDA margin ~29-30%
  5. Sensor and other revenue up 23% to $1.175 billion while hardware revenue declined 19% to $34.2 million
  6. Strong liquidity with $3.32 billion in cash and marketable securities and an undrawn revolving credit facility
  7. Leadership transition: Jake Leach is president and interim CEO; Stelo surpassed $100 million in revenue in its first twelve months

03—Questions

Frequently Asked Questions

  1. Why did DexCom raise its 2025 revenue guidance?

    Revenue grew 22% in the third quarter, with both U.S. and international markets growing at over 20% on a reported basis. Strong sensor demand and expanded access, including the Ontario Drug Benefit Program, supported the higher outlook for the full year.

  2. Is the GAAP earnings beat sustainable?

    Not entirely. GAAP net income of $283.8 million included $82.7 million of income from equity investments, which management excludes from non-GAAP results. Non-GAAP net income was $242.5 million, or $0.61 per diluted share, which is the more representative measure of core operating performance.

  3. What is driving the margin improvement?

    Gross margin on a GAAP basis rose to 60.5% from 59.7%, and operating margin expanded 480 basis points on a GAAP basis, largely because the prior-year quarter included large one-time charges such as a $24.6 million inventory build charge and $25.7 million of IP litigation costs. Non-GAAP operating margin improved a more modest 130 basis points to 22.6%.

  4. Why is hardware revenue declining, and does it matter?

    Hardware revenue fell 19% to $34.2 million as the business shifts toward recurring sensor revenue, which grew 23% and accounts for 97% of total revenue. The decline is consistent with a subscription-style mix and is less of a concern for overall growth, though it bears watching.

  5. What are the key risks highlighted in the filing?

    Investors should monitor the interim CEO leadership transition, workforce reductions and related business transition costs, ongoing patent litigation against Abbott, and the forward-looking statement risks described in DexCom's 10-K and 10-Q filings. Ongoing investment in production capacity also requires continued execution.

04—Continue

← View all 8-K filings